For many cancer survivors, treatment ends but the neuropathy doesn't. Chemotherapy-induced peripheral neuropathy (CIPN) — burning, tingling, numbness, or shooting pain in the hands and feet — can linger for months or years after the last infusion, quietly shaping balance, sleep, and daily life. If you're living with it, here's an honest look at what helps.
What CIPN is and why it lingers
Certain chemotherapy drugs are toxic to peripheral nerves, and the damage doesn't always resolve when treatment stops. The result is often a "glove-and-stocking" pattern of symptoms in the hands and feet — numbness that makes fine tasks hard, burning that intensifies at rest, and unsteadiness that raises the risk of falls. For some survivors it fades with time; for many it becomes a chronic condition in its own right.
The one recommended medication — and its limits
Here the evidence is refreshingly clear, if sobering. In its guideline update, the American Society of Clinical Oncology recommends duloxetine as the sole medication for established painful CIPN — and is explicit that the benefit is limited (ASCO Guideline Update on CIPN). Just as importantly, the update does not recommend gabapentinoids (gabapentin, pregabalin) or tricyclic antidepressants for CIPN, because the evidence didn't support them for this condition.
So the pharmacologic toolkit for CIPN is genuinely thin: one drug, with modest effect. For survivors who don't get enough relief from it — a large group — that's a reason to look beyond medication, not to give up.
When medication isn't enough: target the signal
Instead of adding another systemic drug to a regimen that's already long, neurostimulation targets the pain pathway directly. Peripheral nerve stimulation (PNS) and spinal cord stimulation (SCS) are established, FDA-cleared treatments for chronic neuropathic pain that modulate the signal at the nerve or spinal-cord level — no medication circulating through the body, and none of the systemic side effects that come with it.
CIPN is increasingly managed this way when medication falls short, and the broader evidence for neurostimulation in neuropathic pain is strong — including randomized-trial support and FDA approval for painful diabetic neuropathy, a closely related condition. As with any neuromodulation, the approach is individualized, and candidacy is assessed carefully.
The trial-first advantage for survivors
For someone who has already been through cancer treatment, the last thing you want is another irreversible commitment. That's the quiet strength of this approach: it's reversible and trialed first. A thin lead is placed, you wear an external stimulator for several days, and you judge for yourself whether it meaningfully reduces your pain before any permanent step. If it doesn't help, the lead is removed with no lasting change.
If your symptoms are focused in the feet, our guides on burning feet at night and the long-term side effects of gabapentin may also be useful.
Persistent neuropathy after chemotherapy is not something you simply have to live with. Our 2-minute neuropathy assessment is a plain-language place to start, and you can explore the treatments we offer for chronic nerve pain in more detail.
